Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy at least 12 weeks
Adequate hematologic and end organ function
Negative pregnancy test and willingness to utilize contraception among women of childbearing potential
Locally advanced, recurrent, or metastatic incurable solid malignancy with measurable disease per RECIST v1.1
Progression following at least one standard therapy; or standard therapy considered ineffective, intolerable, or inappropriate; or use of an investigational agent recognized as a standard of care
For the expansion stage, histologically confirmed renal cell cancer (RCC), urothelial bladder cancer (UBC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), gastric cancer, ovarian cancer, cervical cancer, endometrial cancer, or Merkel cell cancer
For the expansion stage, evaluable for PD-L1 expression
Anti PD-1/PD-L1 relapsed cohorts (I and II), participants whose most recent anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade will be enrolled
You may not be if
Significant cardiovascular or liver disease
Major surgery within 28 days of study drug
Any anti-cancer therapy within 3 weeks of study drug
Malabsorption syndrome or poor upper gastrointestinal integrity
Primary central nervous system (CNS) malignancy or active metastases within 5 years
Uncontrolled tumor pain
Autoimmune disease other than stable hypothyroidism or vitiligo
Human immunodeficiency virus (HIV), active hepatitis B or C, or tuberculosis
Signs/symptoms of infection, or use of antibiotics within 2 weeks of study drug
Live attenuated vaccine within 4 weeks of study drug
Known history or predisposition to QT interval prolongation
Prior cancer immunotherapy, specifically indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO) inhibitors, T-cell costimulatory receptor agonist antibodies, or checkpoint inhibitors among certain participants
